专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015066053A3 TARGETED THERAPEUTICS 审中-公开
标题翻译：目标治疗
公开(公告)号：WO2015066053A3
公开(公告)日：2015-11-19
申请号：PCT/US2014062689
申请日：2014-10-28
申请人： SYNTA PHARMACEUTICALS CORP
发明人： CHIMMANAMADA DINESH U , YING WEIWEN
IPC分类号： A61K47/48
CPC分类号： A61K47/48061 , A61K47/545 , A61K49/00
摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
摘要翻译：本发明提供了药理学化合物，其包括与结合部分缀合的效应部分，所述结合部分将效应部分引导至感兴趣的生物学靶标。同样地，本发明提供包含所述化合物的组合物，试剂盒和方法（例如，治疗，诊断和成像）。这些化合物可以描述为蛋白质相互作用的结合部分 - 药物缀合物（SDC-TRAP）化合物，其包括蛋白质相互作用的结合部分和效应器部分。例如，在涉及治疗癌症的某些实施方案中，SDC-TRAP可以包括与作为效应器模块的细胞毒剂缀合的Hsp90抑制剂。

2. 发明申请

WO2015171973A1 PRE-SELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH AN HSP90 INHIBITORY COMPOUND BASED ON CHEMOSENSITIVE STATUS 审中-公开
标题翻译：基于化学状态的HSP90抑制化合物预处理治疗方案的选择
公开(公告)号：WO2015171973A1
公开(公告)日：2015-11-12
申请号：PCT/US2015029811
申请日：2015-05-08
申请人： SYNTA PHARMACEUTICALS CORP
发明人： VUKOVIC VOJO , YALCIN IIKER
IPC分类号： A61K31/41
CPC分类号： A61K31/4196 , A61K31/337 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an Hsp90 inhibitor, alone or in combination with another chemotherapeutic agent, in treating cancer in subjects that are determined to be chemosensitive. In particular, the invention features a method of treating cancer in a subject, comprising administering a Hsp90 inhibitor to the subject, wherein the time since diagnosis of cancer in the subject is 6 months or greater.
摘要翻译：本发明涉及Hsp90抑制剂单独或与另一种化学治疗剂组合用于治疗被确定为化学敏感的受试者中的癌症的用途。特别地，本发明的特征在于一种治疗受试者的癌症的方法，其包括向所述受试者施用Hsp90抑制剂，其中所述受试者中癌症诊断以来的时间为6个月或更长。

3. 发明申请

WO2015038649A1 TARGETED THERAPEUTICS 审中-公开
标题翻译：目标治疗
公开(公告)号：WO2015038649A1
公开(公告)日：2015-03-19
申请号：PCT/US2014/054994
申请日：2014-09-10
申请人： SYNTA PHARMACEUTICALS CORP.
发明人： CHIMMANAMADA, Dinesh, U. , YING, Weiwen , ZHANG, Junyi , KOWALCZYK-PRZEWLOKA, Teresa , JIANG, Jun , OSMAN, Sami , LU, Genliang , VUTUKURI, Dharma , LOCH, James , CHEN, Shoujun
IPC分类号： A61K31/52
CPC分类号： A61K47/48061 , A61K31/167 , A61K31/4184 , A61K31/4188 , A61K31/42 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/495 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/565 , A61K31/58 , A61K31/704 , A61K38/05 , A61K47/545
摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
摘要翻译：本发明提供了药理学化合物，其包括与结合部分缀合的效应部分，所述结合部分将效应部分引导至感兴趣的生物学靶标。同样地，本发明提供包含所述化合物的组合物，试剂盒和方法（例如，治疗，诊断和成像）。这些化合物可以描述为蛋白质相互作用的结合部分 - 药物缀合物（SDC-TRAP）化合物，其包括蛋白质相互作用的结合部分和效应器部分。例如，在涉及治疗癌症的某些实施方案中，SDC-TRAP可以包括与作为效应器模块的细胞毒剂缀合的Hsp90抑制剂。

4. 发明申请

WO2014189937A1 SPECIFIC CANCER TREATMENT REGIMENS WITH GANETESPIB 审中-公开
标题翻译：特定癌症治疗方案与GANETESPIB
公开(公告)号：WO2014189937A1
公开(公告)日：2014-11-27
申请号：PCT/US2014/038796
申请日：2014-05-20
申请人： SYNTA PHARMACEUTICALS CORP.
发明人： VUKOVIC, Vojo
IPC分类号： A61K31/282 , A61K31/337 , A61K31/4196 , A61K31/519 , A61K31/704 , A61P35/00
CPC分类号： A61K31/4196 , A61K31/282 , A61K31/337 , A61K31/519 , A61K31/555 , A61K31/675 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Methods of treating certain types of cancer with ganetespib are disclosed. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with p53 mutation by a combination of ganetespib with a taxane derivative, and a platinum- containing anticancer agent. Also provided are methods of treating certain types of cancer with ganetespib in combination with a platinum-containing anticancer agent, and an antimetabolite. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, an anthracycline derivative, and an alkylating antineoplastic agent. Also provided is a pharmaceutical composition comprising ganetespib and one or more other anticancer agents as described above.
摘要翻译：公开了用甘曲普皮治疗某些类型癌症的方法。还提供了用紫杉烷衍生物与含铂的抗癌剂组合治疗某些类型癌症的方法。本发明还提供了通过格列吡脲与紫杉烷衍生物的组合治疗某些类型的癌症与p53突变的方法和含铂的抗癌剂。还提供了用含有铂的抗癌剂和抗代谢药联合治疗某些类型癌症的方法。还提供了用紫杉烷衍生物，蒽环类衍生物和烷化抗肿瘤剂联合治疗某些类型癌症的方法。还提供了包含如上所述的甘曲西巴和一种或多种其它抗癌剂的药物组合物。

5. 发明申请

WO2013170182A8 TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND 审中-公开
标题翻译：用HSP90抑制化合物治疗癌症
公开(公告)号：WO2013170182A8
公开(公告)日：2014-10-23
申请号：PCT/US2013040594
申请日：2013-05-10
申请人： SYNTA PHARMACEUTICALS CORP
发明人： VUKOVIC VOJO , YALCIN ILKER
IPC分类号： A61P35/00 , A61K31/41 , A61K31/4196
CPC分类号： A61K31/4196
摘要： Methods of treating cancer with ganetespib are disclosed. Also provided are methods of treating a cancer wherein the cancer has a high level of hypoxia, with ganetespib. Also provided are methods of treating a cancer with a mutation in KRAS, a mutation in EGFR, or a mutation in ALK, with ganetespib. Further provided are methods of treating tumor/cancer with a mutation in KRAS, a mutation in EGFR, or a mutation in ALK wherein the tumor/cancer also has certain level of LDH, with ganetespib.
摘要翻译：本发明公开了用甘曲西班苷治疗癌症的方法。还提供了治疗癌症的方法，其中癌症具有高水平的缺氧，具有咽喉炎。还提供了使用格那替普治疗KRAS突变的癌症，EGFR突变或ALK突变的方法。还提供了用KRAS突变，EGFR突变或ALK中的肿瘤/癌症的突变，其中肿瘤/癌症也具有一定水平的LDH的肿瘤/癌症的方法与咽喉炎。

6. 发明申请

WO2013170159A1 TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS 审中-公开
标题翻译：用HSP90抑制化合物治疗癌症
公开(公告)号：WO2013170159A1
公开(公告)日：2013-11-14
申请号：PCT/US2013/040565
申请日：2013-05-10
申请人： SYNTA PHARMACEUTICALS CORP.
发明人： ACQUAVIVA, Jaime , HE, Suqin , PROIA, David
IPC分类号： A61K31/4196 , A61P35/00
CPC分类号： C07D403/04 , A61K31/337 , A61K31/4196 , A61K31/4545 , A61K31/517 , A61K39/395 , A61K45/06 , C07F9/65185 , A61K2300/00
摘要： A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
摘要翻译：一种用于在ROS或RET中具有突变的癌症治疗方法，包括用具有ROS或RET突变的癌症鉴定受试者，以及向所述受试者施用有效量的根据式（I）OR（1a）或互变异构体或其药学上可接受的盐，其中变量结构式在本文中定义。

7. 发明申请

WO2012162293A1 COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS 审中-公开
标题翻译： HSP90抑制剂与MEK抑制剂的联合治疗
公开(公告)号：WO2012162293A1
公开(公告)日：2012-11-29
申请号：PCT/US2012/038950
申请日：2012-05-22
申请人： SYNTA PHARMACEUTICALS CORP. , PROIA, David , ACQUAVIVA, Jaime
发明人： PROIA, David , ACQUAVIVA, Jaime
IPC分类号： A61K31/4196 , A61K31/675 , A61K45/06 , A61K31/416 , A61K31/166 , A61K31/277 , A61K31/352 , A61K35/00
CPC分类号： A61K31/4196 , A61K31/166 , A61K31/277 , A61K31/352 , A61K31/416 , A61K31/4184 , A61K31/675 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprising an MEK inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) or tautomers or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
摘要翻译：包含MEK抑制剂和根据下式（I）或（Ia）的Hsp90抑制剂或其互变异构体或其药学上可接受的盐的药物组合物，其中结构式中的变量在本文中定义。还提供了使用本文所述的药物组合物治疗有需要的受试者的增殖性病症的方法。

8. 发明申请

WO2012155063A1 TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND 审中-公开
标题翻译：用HSP90抑制化合物治疗癌症
公开(公告)号：WO2012155063A1
公开(公告)日：2012-11-15
申请号：PCT/US2012/037564
申请日：2012-05-11
申请人： SYNTA PHARMACEUTICALS CORP. , VUKOVIC, Vojo
发明人： VUKOVIC, Vojo
IPC分类号： A01N43/64 , A61K31/41
CPC分类号： A61K31/4196 , A61K31/337 , A61K31/4545 , A61K31/4745 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
摘要： Methods of treating cancer with a compound of formula (I) are disclosed. Also provided are methods of treating a cancer with a KRAS mutation or an ALK+ cancer with a compound of formula (I). Further provided are methods of treating KRAS- mutated or ALK+ NSCLC with a compound of formula (I).
摘要翻译：公开了用式（I）化合物治疗癌症的方法。还提供了用式（I）化合物用KRAS突变或ALK +癌治疗癌症的方法。还提供了用式（I）化合物治疗KRAS-突变或ALK + NSCLC的方法。

9. 发明申请

WO2012078757A3 COMBINATION FOR BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS 审中-公开
公开(公告)号：WO2012078757A3
公开(公告)日：2012-06-14
申请号：PCT/US2011/063742
申请日：2011-12-07
申请人： SYNTA PHARMACEUTICALS CORP. , PROIA, David
发明人： PROIA, David
IPC分类号： A61K31/138 , A61K31/4196 , A61K31/675 , A61K45/06 , A61P35/00
摘要： Methods for treating breast cancer, comprising administering to the subject an effective amount of a selective estrogen receptor modulator and an effective amount of a compound represented by the following structural formula: (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.

10. 发明申请

WO2012068491A1 PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH ELESCLOMOL BASED ON HYPOXIC STATUS 审中-公开
标题翻译：基于HYPOXIC状态的ELESCLOMOL治疗方案的选择
公开(公告)号：WO2012068491A1
公开(公告)日：2012-05-24
申请号：PCT/US2011/061453
申请日：2011-11-18
申请人： SYNTA PHARMACEUTICALS CORP. , BLACKMAN, Ronald, K. , VUKOVIC, Vojo
发明人： BLACKMAN, Ronald, K. , VUKOVIC, Vojo
IPC分类号： A61K31/165 , A61P35/00
CPC分类号： A61K31/166 , A61K31/165 , C12Q1/6886 , G01N33/57484
摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase (LDH). The invention also provides methods for treating cancer in a subject by administering an effective amount of elesclomol to the subject, wherein the subject has a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
摘要翻译：本发明提供了基于受试者中调节的缺氧水平预先选择受试者治疗性脑脊髓炎的方法。在一个实施方案中，本发明提供了基于调节水平的乳酸脱氢酶（LDH）预先选择受试者治疗性脑炎的方法。本发明还提供了通过向受试者施用有效量的elesclomol来治疗受试者的癌症的方法，其中受试者具有调节的缺氧水平。本发明还提供实施本发明方法的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式